SCHEMBL25025173

SCHEMBL25025173

C[C@H]1c2c(nn(-c3ccc(F)c(C(F)(F)F)c3)c2N)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.36
▸ NR1H2 P55055 2/20 0.36
▸ NR1H3 Q13133 1/20 0.36
▸ PREP P48147 1/20 0.36
▸ GPR119 Q8TDV5 2/20 0.35
▸ AR P10275 6/20 0.35
▸ C5AR1 P21730 1/20 0.34
▸ RIPK1 Q13546 1/20 0.33
▸ ACACB O00763 2/20 0.33
▸ RORC P51449 1/20 0.33
▸ UGCG Q16739 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ HPGDS O60760 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21183670 0.89 THRB (0.37) NR1H2NR1H3GPR119C5AR1HPGDS
SCHEMBL25025175 0.83 PREP (0.34) NOTUMNR1H2NR1H3PREPGPR119
SCHEMBL28952435 0.82 NR1H2 (0.33) NR1H2NR1H3C5AR1ACACBHPGDS
SCHEMBL20014821 0.82 NR1H2 (0.33) NR1H2NR1H3C5AR1ACACBHPGDS
SCHEMBL25025177 0.80 NTRK1 (0.36) NOTUMNR1H2NR1H3PREPGPR119
SCHEMBL20015355 0.79 NR1H2 (0.33) NR1H2C5AR1ACACB
SCHEMBL38651835 0.79 F12 (0.32) NR1H2C5AR1
SCHEMBL31692192 0.77 LMNA (0.34) NR1H2NR1H3C5AR1
SCHEMBL31472143 0.76 GPR119 (0.33) NR1H2NR1H3GPR119ARC5AR1
SCHEMBL25025174 0.76 GLP1R (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 — — US disclosed
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 — — US disclosed
US-11584751-B1 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE (SHANGHAI) CO., LTD. (CN) 2023-02-21 — — US disclosed
US-20230051320-A1 TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME ECCOGENE INC. 2023-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584751-B1 Substituted imidazoles as GLP-1 receptor agonists GLP1R, GIPR, SLC5A1 NOTUM 3806/4885NR1H2 952/4885NR1H3 1319/4885
US-20230051320-A1 TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME GLP1R, SLC5A1, GIPR NOTUM 1996/4885NR1H2 1105/4885NR1H3 1468/4885
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists GLP1R, GIPR, SLC5A1 NOTUM 3806/4885NR1H2 952/4885NR1H3 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback